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The reactions of two analogues of 4-aminobutyrate, namely 4-aminohex-5-ynoate and 4-aminohex-5-enoate, with three transaminases were studied. Three pure enzymes were used, aminobutyrate transaminase (EC 2.6.1.19) , ornithine transaminase (EC 2.6.1.13) and aspartate transaminase (EC 2.6.1.1), and the course of the reactions was studied by observing changes in the absorption spectrum of the bound coenzyme and by observing loss of activity. All of the enzymes were inactivated by either inhibitor, but aminohexenoate showed a marked specificity for aminobutyrate transaminase. Aminohexynoate was most potent towards ornithine transaminase, and with this enzyme transamination of the inhibitor is an important factor in protecting the enzyme. Most of the reactions could be analysed as first order, with the observed rate constant showing a hyperbolic dependence on inhibitor concentration.
Ideally compounds intended to act as drugs by specific inhibition of a particular metabolic step should show an absolute selectivity towards the target enzyme. One means of approaching this ideal is to prepare a compound that not only bears a strong structural resemblance to the substrate, but also becomes reactive as an irreversible inhibitor only as a result of the operation of the enzyme's normal mechanism. The pharmacological potential of such enzyme-induced irreversible inhibition has been pointed out Rando, 1974a) and inhibitors of this type have been referred to as 'k,2,. inhibitors' (Rando, 1974a) and 'suicide enzyme inactivators' (Abeles & Maycock, 1976) .
Several inhibitors ofthis type have been synthesized with the intention of selectively inhibiting 4-aminobutyrate transaminase (EC 2.6.1.19) (Fowler & John, 1972; Jung & Metcalf, 1975; Lippert et al., 1977) . The inhibition of this enzyme by a naturally occurring compound, gabaculine (5-amino-1,3-cyclohexadienyl carboxylic acid), is also by an enzyme-induced mechanism (Rando & Bangerter, 1977) . Aminobutyrate transaminase has received attention because its substrate is an inhibitory neurotransmitter, and therefore its selective inhibition is pharmacologically interesting.
The reactions of pyridoxal phospha-e-dependent enzymes with substrate analogues of this kind may be complex, as is shown by the reaction of the glutamate analogue, serine sulphate, with aspartate transaminase . In this case the enzyme catalyses the elimination of sulphate from the f4-position, and there is evidence indicating that Vol. 177 the resulting aminoacrylic intermediate reacts with lysine-258 and cysteine-390 of the enzyme (John et al., 1973) . However, in addition there is a slow transamination that protects the enzyme from further inactivation, because the pyridoxamine form of the enzyme, although fully active in the normal transamination reaction, cannot combine productively with amino acids. If inhibition is investigated without regard to the possibility of a protecting transamination it could be wrongly concluded that a compound does not inhibit a particular enzyme. Furthermore, the goal of very high specificity, which the enzymeinduced type of inhibition might be expected to approach, may be made less easily attainable because of the existence of families of enzymes that share the same catalytic mechanism.
Two compounds, namely 4-aminohex-5-ynoic acid and 4-aminohex-5-enoic acid, which might be considered as acetylenic and vinyl derivatives of 4-aminobutyrate, have been prepared as enzymeinduced inhibitors of aminobutyrate transaminase (Jung & Metcalf, 1975; Lippert et al., 1977) . They inactivate the enzyme, and the mechanism proposed is one suggested for the inactivation of aspartate transaminase by 2-aminobut-3-enoic acid (Rando, 1974b) , in which the enzyme induces reactivity by introducing conjugation of double bonds. The inhibitors were also shown, by measuring rates of loss of activity, to be relatively inert towards impure preparations of some other pyridoxal enzymes.
The present paper is an account of investigations into the reactions of these compounds with some transaminases. The enzymes used were all purified to homogeneity and the study depends heavily on observation of changes in the absorption spectrum of the bound coenzyme. As well as aminobutyrate transaminase, aspartate transaminase (EC 2.6.1.1) and ornithine transaminase (EC 2.6.1.13) were studied, the last particularly because, like aminobutyrate transaminase, it catalyses transamination of amino groups on carbon atoms that bear no carboxy group.
Experimental Enzymes
Experiments with aspartate transaminase were carried out with the pure x-subform of the pig heart cytoplasmic enzyme prepared by the method of Martinez-Carrion et al. (1967) . Ornithine transaminase was prepared from rat liver by the method of Peraino et al. (1969) and 4-aminobutyrate transaminase from rabbit brain by the method of John & Fowler (1976) . Enzyme concentrations are expressed as concentration of bound pyridoxal phosphate and were determined by using E280=7x 104 M-l-cm-l for aspartate transaminase (Birchmeier et al., 1973) John, unpublished work) . The concentration of the last enzyme was also determined by titration with amino-oxyacetate (John et al., 1978) .
Chemicals
The inhibitors 4-aminohex-5-ynoic acid and 4-aminohex-5-enoic acid were a gift from Merrell International Research Centre, Strasbourg, France. Tris (Puriss grade) and 2-oxoglutaric acid were from Koch-Light Laboratories, Colnbrook, Bucks., U.K. Aspartic acid, ornithine and 4-aminobutyrate were from Sigma (London) Chemical Co., London SW6, U.K. Other chemicals used were supplied by BDH Chemicals, Poole, Dorset, U.K.
Enzyme activity assays
Aspartate transaminase was assayed by the method of Karmen (1955) , ornithine transaminase by the method of Peraino & Pitot (1963) and aminobutyrate transaminase by the method of Salvador & Albers (1959) .
Absorption spectra
Absorption spectra were determined on a Beckman model 25 recording spectrophotometer.
Determination ofkinetic constants
When, graphically, the observed first-order rate constants for inhibition (kobs.) were found to vary hyperbolically with inhibitor concentration, the results were taken to indicate the initial formation of significant amounts of a rapidly reversible complex The dissociation constant, K, for complex formation, and the first-order rate constant, k, for irreversible inhibition were estimated using a weighted leastsquares linear-regression analysis. Simple errors in kObs. were assumed and weights of ko2bs.I[1]2 were used. The method used was that described by Wilkinson (1961) 
Results and Discussion
The results of the experiments on all three enzymes and with both substrates will be interpreted in terms of Schemes 1(a) and l(b) which are based on the classical Snell-Braunstein mechanism for transamination (Braunstein, 1964; Guirard & Snell, 1964) . Inactivation will be presumed to occur as a result of reaction of a nucleophile in the enzyme with either or perhaps both of the reactive intermediates El' and EKI'. Several plausible routes are possible all leading effectively to the same result, namely covalent binding of the enzyme-induced inhibitor to the enzyme protein.
Reactions ofaminobutyrate transaminase The changes in coenzyme absorption spectrum that are seen when aminobutyrate transaminase reacts with aminohexynoate occur in two phases and the rates of each phase are dependent on inhibitor concentration. Fig. 1 shows the changes that occur when the enzyme is treated with 0.63 mM-aminohexynoate. Distinct changes are seen at three wavelengths. Initially a rapid decrease at 412nm is accompanied by rapid increases at 330 and 550nm. Thereafter a slow decrease at both 412 and 550nm is accompanied by a further rise at 330nm. The course of these reactions followed at 412 and 550nm is shown in Fig. 2 . The slow process is first order, with the same rate constant that is observed when loss of enzyme activity is followed. This rate constant, measured by activity loss, showed a hyperbolic dependence on inhibitor concentration. The constants were estimated by measuring loss of activity ( We interpret these changes by suggesting that the fast process involves formation of an intermediate with extensive double-bond conjugation due to removal of a proton by the catalytic action of the enzyme (Scheme 1). However, many of the steps of Scheme 1 are not evident and it may be simplified to allow for a number of observations. Firstly exponential loss of activity continues to zero even in the absence of 2-oxoglutarate, which indicates that complete transamination to the free pyridoxamine form of the enzyme (Em) does not occur extensively at this enzyme concentration. There is an initial rapid increase at 330nm which occurs at the same rate as the increase at 550nm and the rapid part of the fall at 412nm. This may be assigned to an enzymeinhibitor complex in rapid equilibrium with the Time (min) Fig. 2 . Course ofthe reaction between aminohexynoate and aminobutyrate transaminase Aminobutyrate transaminase (7pM) was reacted with aminohexynoic acid (3.3 mM). The course of the reaction was followed continuously at 550nm (a) and 412nm (b). Experimental conditions as in Fig. 1 . Using the values obtained for the fast rate constant together with the relationships K=L/k+j1=1.3mm and kF=k+l+k-l the values for k,j and k-L were determined to be 12.3±2.1M-1's-1 and 0.016+ 0.003 s-'. The changes seen when aminobutyrate transaminase was treated with the vinyl analogue, aminohexenoate, were accompanied by a spectral shift from the 412 nm-absorbing internal aldimine to a species absorbing at 330nm. In this case the reaction was rapid compared with the time required to scan the spectrum. When followed continuously at 412nm the process appeared first order throughout its course, and whereas with the acetylenic compound changes in concentration of an intermediate absorbing at 550nm were measurable, the increase at higher wavelengths seen with the vinyl analogue was very small. The extent of this change was about 20% of that seen with aminohexynoate and the wavelength of maximum absorbance difference was about 470nm. The absorbance changes were too small to allow the kinetics of changes at this wavelength to be followed.
Loss of activity and decrease in absorbance at 412nm occurred exponentially at the same rate and kObS. showed hyperbolic dependence on inhibitor concentration. The kinetic constants were found by measuring loss of activity under the conditions described for aminohexynoate and are given in Reactions with ornithine transaminase Ornithine transaminase shares with aminobutyrate transaminase the property of transaminating amino groups from carbon atoms which do not bear a carboxy group. Both aminohexynoate and aminohexenoate react with this enzyme and the results can be fully explained in terms of Scheme 1. Inactivation and transamination occur in both cases, but because the difference in rates of the two processes is greater with the vinyl derivative the two processes can be more clearly separated. Fig. 3 shows the spectral changes that occur when aminohexenoate reacts with ornithine transaminase. Throughout the period of this experiment and for a further 20min there was no significant loss of activity. Addition of 2-oxoglutarate (5mM) restored the original spectrum, indicating that the original spectral shift was due to transamination of the aldimine form of the enzyme to the amine form. When the enzyme was treated with the same concentration of aminohexenoate, but in the presence of 2-oxoglutarate (5mM), the spectral changes shown in Fig. 4 seen. This process is much slower than the transamination, gives rise to increased absorbance at 310nm rather than at 330nm, and is accompanied by loss of activity. The enzyme eventually becomes completely inactive and has the absorption spectrum shown in Fig. 4 Wavelength (nm) Fig. 4 . Effect of2-oxoglutarate on the reaction between aminohexenoate and ornithine transaminase (a) Ornithine transaminase (24pM) was treated with 1.6mM-aminohexenoate. The spectrum with highest absorbance at 412nm is that before adding inhibitor, but with 2-oxoglutarate present. Experimental conditions were as in Fig. 3. (b) This shows the spectrum of the product using a different scale expansion to include the shoulder at 310nm formed as a result of the reaction. Addition of 2-oxoglutarate to a final concentration of 2mM did not reverse any of the spectral change, and when this compound was included in the reaction mixture at the start the only effect was to slow the reaction slightly. This decrease in the rate of inhibition may be attributed to the formation of a small amount of abortive complex between the aldimine enzyme and 2-oxoglutarate (Jenkins & D'Ari, 1963) .
Comparison of the efficacy of such compounds should take account both of the rapidly reversible part of the reaction and of the irreversible part, and in order to make a numerical comparison the ratio k/K would provide a useful index of specificity.
It is clear that neither of these compounds approaches absolute specificity towards aminobutyrate transaminase. In fact, aminohexynoate is more potent towards ornithine transaminase. However, aminohexenoate is 3 times more effective than aminohexynoate towards aminobutyrate transaminase and its reactivity towards the other enzymes is relatively very slight.
The results obtained with ornithine transaminase show that even at low concentrations of either inhibitor, transamination of the enzyme to EM goes to completion. This suggests that the keto acid products of the inhibitors are unstable, probably reacting with water. With the other two enzymes release of these products must be slow relative to the irreversible reaction with enzyme. The differences in absorption spectrum of the final inactive product could indicate that different paths to inactivation exist via both El' and EKI'. Another explanation could be that the covalent adduct continues to undergo an enzyme-catalysed tautomerization. This would explain why both 310 
